Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21F2N7O2 |
Molecular Weight | 417.4125 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)C1=NC2=C(C=CC=C2)N1C3=NC(=NC(=N3)N4CCOCC4)N5CCOCC5
InChI
InChIKey=HGVNLRPZOWWDKD-UHFFFAOYSA-N
InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/?term=16622124Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22349137; https://www.ncbi.nlm.nih.gov/pubmed/23812078
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=16622124
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22349137; https://www.ncbi.nlm.nih.gov/pubmed/23812078
ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs. Specifically, ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. ZSTK474 blocks VEGF-induced cell migration and the tube formation in human umbilical vein endothelial cells (HUVECs), and inhibits the expression of HIF-1α and secretion of VEGF in RXF-631L cells, exhibiting potent in vitro antiangiogenic activity. ZSTK474 demonstrated prophylactic efficacy in a rat model of rheumatoid arthritis (RA) through inhibition of T cell and FLS functions.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27553832
Curator's Comment: Study of glioblastoma mouse models did not reviled an increased brain penetration of ZSTK474 relative to WT mice. Another study reports that ZSTK474 reduces CNS inflammation and demyelination of EAE mice (https://www.ncbi.nlm.nih.gov/pubmed/24844601).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O00329 Gene ID: 5293.0 Gene Symbol: PIK3CD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17711503 |
1.8 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://jnci.oxfordjournals.org/content/98/8/545.long
ZSTK474 at 100, 200, or 400 mg/kg of mice body weight was orally administered daily from days 0 to 13.
Route of Administration:
Oral
Human prostate cancer PC3 cells growth inhibition was determined using the WST-8 assay kit. One hundred uL of cells (6 × 104 cells/mL) was seeded in 96-well plate and incubated at 37 °C. Twenty four hours later, 0.5 uL of various stock solutions of ZSTK474 was added. After further incubation for 48 h, 10 uL of WST-8 was added to each well and the cells were further incubated at 37 °C. Three hours later, the absorbances at 450 nm were measured with a microplate spectrophotometer.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C95723
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
K0068GK39A
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
475110-96-4
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
DB12904
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
11647372
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
DTXSID30197179
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
90545
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL586701
Created by
admin on Fri Dec 15 19:50:58 GMT 2023 , Edited by admin on Fri Dec 15 19:50:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY